Seroprevalence of SARS-CoV-2 Infection Among Working Women and Impact of Workplace Restrictions

References

• Al Kuwari HM, Abdul Rahim HF, Abu-Raddad LJ, et al. Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February–18 April 2020. BMJ Open. 2020;10(10):e040428. doi:10.1136/bmjopen-2020-040428
   PubMed Web of Science ®Google Scholar
• Della Valle P, Fabbri M, Madotto F, et al.; The MUSTANG–OCCUPATION–COVID-19 Study Group. Occupational exposure in the Lombardy Region (Italy) to SARS-CoV-2 infection: results from the MUSTANG–OCCUPATION–COVID-19 study. Int J Environ Res Public Health. 2021;18(5):2567. doi:10.3390/ijerph18052567
   PubMed Web of Science ®Google Scholar
• Alajmi J, Jeremijenko AM, Abraham JC, et al. COVID-19 infection among healthcare workers in a national healthcare system: the Qatar experience. Int J Infect Dis. 2020;100:386–389. doi:10.1016/j.ijid.2020.09.027
   PubMed Web of Science ®Google Scholar
• Butt AA, Kartha AB, Masoodi NA, et al. Hospital admission rates, length of stay, and in-hospital mortality for common acute care conditions in COVID-19 vs. pre-COVID-19 era. Public Health. 2020;189:6–11. doi:10.1016/j.puhe.2020.09.010
   Web of Science ®Google Scholar
• Ayoub HH, Chemaitelly H, Seedat S, et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021;11:05005. doi:10.7189/jogh.11.05005
   Web of Science ®Google Scholar
• Biggs HM, Harris JB, Breakwell L, et al; CDC Field Surveyor Team (2020). Estimated community seroprevalence of SARS-CoV-2 antibodies - two Georgia counties, April 28–May 3, 2020. MMWR. 2020;69(29):965–970. doi:10.15585/mmwr.mm6929e2
   PubMed Web of Science ®Google Scholar
• Muench P, Jochum S, Wenderoth V, et al. Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol. 2020;58. doi:10.1128/JCM.01694-20
   Web of Science ®Google Scholar
• The Roche Group. Roche’s COVID-19 antibody test receives FDA emergency use authorization and is available in markets accepting the CE mark. Available from:https://www.roche.com/media/releases/med-cor-2020-05-03.htm. Accessed June 5, 2020.
   Google Scholar
• Thermo fisher scientific TaqPath™ COVID‑19 CE‑IVD RT‑PCR Kit instructions for use. Available from: https://assets.thermofisher.com/TFSAssets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf. Accessed December 2, 2020.
   Google Scholar
• Kalikiri MKR, Hasan MR, Mirza F, et al. High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads. medRxiv. 2020. doi:10.1101/2020.04.08.20055731
   Google Scholar
• Kubina R, Dziedzic A. Molecular and serological tests for COVID-19 a comparative review ofSARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics. 2020;10:434. doi:10.3390/diagnostics10060434
   Web of Science ®Google Scholar
• Alishaq M, Jeremijenko A, Nafady-Hego H, et al. SARS-CoV-2 infection in mortuary and cemetery workers. Int J Infect Dis. 2021;105:621–625. doi:10.1016/j.ijid.2021.03.012
   Web of Science ®Google Scholar
• Alishaq M, Jeremijenko A, Nafady-Hego H, et al. SARS-CoV-2 PCR and antibody positivity among school staff at the beginning and end of the first school term. BMC Public Health. 2021;21(1):2070. doi:10.1186/s12889-021-12134-4
   Web of Science ®Google Scholar
• Alishaq M, Jeremijenko A, Al-Kanaani Z, et al. Prevalence and risk factors for SARS-CoV-2 infection and seroprevalence among clinical and non-clinical staff in a national healthcare system. PLoS One. 2021;16(9):e0257845. doi:10.1371/journal.pone.0257845
   Web of Science ®Google Scholar
• Alishaq M, Nafady-Hego H, Jeremijenko A, et al. Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. PLoS One. 2021;16(10):e0258820. doi:10.1371/journal.pone.0258820
   Web of Science ®Google Scholar
• Jeremijenko A, Chemaitelly H, Ayoub HH, et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. Emerg Infect Dis. 2021;27(5):1343–1352. doi:10.3201/eid2705.204365
   Web of Science ®Google Scholar
• Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. iScience. 2021;24(6):102646. doi:10.1016/j.isci.2021.102646
   Web of Science ®Google Scholar
• Sikkema RS, Pas SD, Nieuwenhuijse DF, et al. COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study. Lancet Infect Dis. 2020;20(11):1273–1280. doi:10.1016/S1473-3099(20)30527-2
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci Rep. 2021;11(1):6233. doi:10.1038/s41598-021-85428-7
   Web of Science ®Google Scholar
• Al-Thani MH, Farag E, Bertollini R, et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open Forum Infect Dis. 2021;8(8). doi:10.1093/ofid/ofab221
   Web of Science ®Google Scholar
• Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970–971. doi:10.1056/NEJMc2001468
   PubMed Web of Science ®Google Scholar
• Kim ES, Chin BS, Kang CK, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19. J Korean Med Sci. 2020;35(13):e142. doi:10.3346/jkms.2020.35.e142
   PubMed Web of Science ®Google Scholar
• Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407. doi:10.1001/jama.2020.2565
   PubMed Web of Science ®Google Scholar